/
FBRX
$21.32+$0.29 (+1.38%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$430.7M
20M shares
52-week range
$9.10 – $35.80
46% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.46%
Moderate
Price (6 mo)
Loading chart…
Change$-852.93
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $11.0K | $54.0K | $36.0K | $0 | $9.0K | $39.0K | $64.0K |
| Gross profit | $18.0M | −$11.0K | −$54.0K | −$36.0K | $0 | −$9.0K | −$39.0K | −$64.0K |
| Gross margin | 100.0% | — | — | — | — | — | — | — |
| R&D | $50.5M | $2.7M | $9.9M | $13.9M | $5.6M | $21.9M | $21.2M | $58.2M |
| Operating income | −$45.9M | −$4.1M | −$14.2M | −$21.5M | −$13.9M | −$32.5M | −$36.6M | −$70.7M |
| EBITDA | −$43.7M | −$4.1M | −$46.4M | −$21.7M | −$13.8M | −$31.5M | −$35.4M | −$68.3M |
| Net income | −$49.0M | −$4.1M | −$46.5M | −$21.7M | −$13.9M | −$31.5M | −$35.5M | −$69.4M |
| Net margin | -271.4% | — | — | — | — | — | — | — |
| EPS (diluted) | -915.18 | -48.25 | -157.93 | -38.85 | -19.96 | -24.92 | -12.17 | -4.71 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $9M | $-4.11 | $-4.31–$-3.90 | 4 |
| 2027 | $23M | $-4.25 | $-5.71–$-2.79 | 4 |
| 2028 | $14M | $-4.17 | $-5.46–$-2.49 | 3 |
| 2029 | $32M | $-5.93 | $-5.93–$-5.93 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.47
Price
$21.32
Implied downside
-98%
Peer comparison
Forte Biosciences, Inc. Common Stock
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
www.fortebiorx.com- Employees
- 22
- IPO / List date
- Jun 16, 2020
- HQ
- DALLAS, TX
Held by traders on TradeandTell
No one on the platform currently holds FBRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 16,200 | $243.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-28 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded FBRX yet.
